Tirzepatide Side Effects and Safety
Reported Tirzepatide side effects, contraindications, and safety signals.
Safety & Contraindications
Tirzepatide is a research compound and is not FDA-approved for general use. It should be avoided by anyone with personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, and pregnancy. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
What to Monitor
Track body weight, waist circumference, HbA1c, fasting glucose, fasting insulin, and triglycerides while you're running Tirzepatide so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
Contraindications
- personal/family history of medullary thyroid carcinoma
- MEN 2
- pancreatitis
- pregnancy
References
- Tirzepatide Once Weekly for the Treatment of Obesity
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
- Tirzepatide - StatPearls - NCBI Bookshelf
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.